Gastrointestinal Therapeutics Market in US, UK, France, Germany, Italy, Spain, Japan and Canada is Expected to Decline at a CAGR of 0.3% between 2012 and 2019, Reveals New Report

Gastrointestinal Therapeutics in Major Developed Markets to 2019 New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries report provides insights into three gastrointestinal therapeutic indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of three gastrointestinal therapeutics markets, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications.

In 2012, the value of the gastrointestinal therapeutics market in major developed countries amounted to an estimated $6.8 billion. This total is forecast to decline at a Compound Annual Growth Rate (CAGR) of 0.3% between 2012 and 2019. The value of the IBS market amounted to an estimated $727m, and is forecast to increase at a CAGR of 14.4% between 2012 and 2019. The value of the UC market amounted to an estimated $2.2 billion in 2012, and is expected to increase at a CAGR of 6% during the forecast period. The value of the CD market amounted to an estimated $3.8 billion, which is expected to decline at a CAGR of 7.5% between 2012 and 2019.

Scope

• The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals for the IBS, UC and CD indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada.
• Disease overview and treatment usage patterns
• Market size and forecast for IBS, UC and CD in major developed markets from 2012 to 2019
• Major marketed products for the indication types covered
• In-depth pipeline analysis for IBS, UC and CD
• Key drivers and restraints that have had and are expected to have a major impact upon the market
• Key licensing and co-development agreements in the gastrointestinal therapeutics market

Reasons to buy

• Align your product portfolio to the markets with high growth potential
• Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments that are poised for strong growth
• Devise a more effectively tailored country-specific strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market
• Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Spanning over 90 pages, “Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries” report covering the Gastrointestinal Therapeutics in Major Developed Markets – Introduction, Gastrointestinal Therapeutics in Major Developed Markets – Marketed Products (Global), Gastrointestinal Therapeutics in Major Developed Markets – Pipeline Analysis, Gastrointestinal Therapeutics in Major Developed Markets – Market Forecast to 2019, Gastrointestinal Therapeutics in Major Developed Markets – Deals and Strategic Consolidations (Global), Gastrointestinal Therapeutics in Major Developed Markets – Appendix.

Know more about this report: http://mrr.cm/ZBq

Epilepsy Therapeutics Market in US, UK, France, Germany, Italy, Spain, Japan and Canada is expected to grow at a CAGR 3.9% to reach $4.5 billion by 2019, Reveals New Report

"Epilepsy Therapeutics in Major Developed Markets to 2019 New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns", which provides in-depth analysis of epilepsy market within the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the epilepsy market in the major developed markets amounted to an estimated $3.4 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 3.9% to reach $4.5 billion by 2019. This modest growth is attributed to the recent approval of drugs with novel mechanisms of action that are expected to offer more therapeutic options to prescribers. The US takes major share of 55% of the global epilepsy market. In the US, three new anti-epileptic drugs have been approved since 2012: Trobalt, Aptiom, and Fycompa and another, brivaracetam, is expected also to be launched during the forecast period. Of these, Trobalt and Fycompa have novel mechanisms of action and improved safety and tolerability that elicited significant interest from prescribers. Continued uptake of secondand third-generation anti-epileptic drugs is also expected to contribute towards revenues in these eight regions. However, the epilepsy market could face the restricting influence of generic competition as a result of recent patent expiries in all major markets of two key branded drugs, Keppra and Lamictal.

Scope

• A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options
• In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters
• A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target
• Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action
• Multi-scenario forecasts of the epilepsy market over the 2012–2019 period in the eight major developed markets
• In-depth analysis of licensing and co-development agreements and an overview of key agreements that could impact growth trends
• Key drivers and restraints that have had and are expected to have a significant impact upon the market

Reasons to buy

• Align your product portfolio to markets with high growth potential
• Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
• Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the anti-epileptic drugs market
• Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Spanning over 74 pages, “Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns” report covering the Introduction, Epilepsy Therapeutic Landscape, Pipeline for Epilepsy Therapeutics, Epilepsy Therapeutics Market Forecast to 2019, Deals and Strategic Consolidations, Appendix.

Know more about this report: http://mrr.cm/ZBT

Breast Cancer Therapeutics Market in India, Australia, China and Japan is expected to grow at a CAGR of 7.6% to $2.5 billion by 2020, Reveals New Report

“Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 Novel HER-2 Positive Therapies Provide Diversified Treatment Options” report provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The breast cancer therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020. Japan had the largest market in 2013 with a value of $872m, or a share of 58%, followed by China with $320m or 21%, and Australia with $234m or 16%. India had the lowest market share and value at 5% and $81m, but is expected to witness the fastest growth over the forecast period with a CAGR of 13.8%, compared to Australia at 7.8% and China and Japan both at 7.7%.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the - breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan.The report includes:

• Disease overview, as well as treatment algorithms and treatment usage patterns
• Market size and forecast for the APAC breast cancer market from 2013 to 2020
• Major marketed products in the APAC region along with a heat map of product performance
• In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis
• Key drivers and restraints that have had and are expected to have a significant impact upon the market
• Key licensing and co-development agreements that could have impact on growth trends

Reasons to buy

The report will enhance your decision-making capability by allowing you to:

• Align your product portfolio to the markets with high growth potential
• Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
• Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer drugs market
• Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Spanning over 103 pages, “Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options” report covering the Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 -Introduction, Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Marketed Products, Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Pipeline Analysis,  Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Market Forecast to 2020, Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Deals and Strategic Consolidations, Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Appendix.

Know more about this report: http://mrr.cm/ZNr

Ovarian Cancer Therapeutics Global Market is Rise at a Limited CAGR of 3.4% to $1.9billion in 2020, Reveals New Report

“Ovarian Cancer Therapeutics in Major Developed Markets to 2020 Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies”, The current Ovarian cancer therapeutics market is dominated by the use of generics – predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). Initial treatment with platinum-based therapy is usually effective, with approximately 70% of patients entering remission. However, even with extended progression free-survival of 24 months, almost all patients relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor.

There is a clear gap in the market for maintenance therapies to extend the initial high rates of remission, and hopefully stimulate long-term remission in patients. As well as a gap for more effective treatment options in platinum-resistant or refractory patients.

The current developmental pipeline addresses these gaps in the market, with five of the 10 late stage pipeline molecules indicated as maintenance therapies, and three of the 10 indicated in platinum-resistant disease. However, efficacy with these late stage drugs has been poor, at best demonstrating minimal improvements in PFS. In the EU, both Avastin and Yondelis have been approved on the basis of improvements in PFS alone. It is expected therefore, that those pipeline drugs that have demonstrated the most significant improvements in PFS – olaparib, Vynfinit and trebananib, will be approved in this territory. However even on approval, the lack of an overwhelming improvement in clinical benefit with these drugs, and their expected high cost will limit their sales. In the US, the improvement in PFS observed with Yondelis and Avastin, in the absence of any other clinical benefit with either drug, resulted in neither drug being approved by the FDA. In line with these rejections, the improvements in PFS alone, observed with the current late stage pipeline drugs, is expected to result in the failure of any drug to be approved in the US within the forecast period.

As a result the global market is expected not be driven by new drug approvals, but primarily inflation, and the increase in the prevalence of pancreatic cancer. Global market revenues are forecast to rise at a limited CAGR of 3.4% to $1.9billion in 2020.

Despite the poor results obtained with late stage pipeline drugs there is evidence of continued interest in the ovarian cancer market, with a high number of drug candidates in the current developmental pipeline, particularly at the Preclinical Phase. There is a wide range of novel molecular targets distributed amongst these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in other indications in oncology.

Scope

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for pancreatic cancer. The report covers and includes:

• A brief introduction to ovarian cancer, including the disease’s pathogenesis, risk factors and diagnosis.
• In-depth analysis of the drug combinations used in the treatment of ovarian cancer, including analyses of their safety, efficacy, and place in the disease treatment algorithm. This includes a heat map comparing the drug combination in terms of safety and efficacy.
• Comprehensive review of the pipeline for ovarian cancer therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.
• Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.
• Multi-scenario forecast data of the market to 2020, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Canada, Japan, Germany, the UK, France, Italy and Spain.
• Discussion of the drivers and barriers for market growth.
• An in-depth analysis of licensing and co-development deals involving drugs indicated in ovarian cancer, including an in-depth outline of the key deals.

Reasons to buy

• The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to
• Understanding the efficacy and safety of the current monotherapies and drug combinations used in the treatment of ovarian cancer, with an in-depth analysis of the disease treatment algorithm.
• Understand the key signalling pathways and molecular targets currently inder investigation in drug development for ovarian cancer
• Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
• Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for pancreatic cancer therapeutics.
• Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the ovarian cancer therapeutics market.

Spanning over 148 pages, “Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies” report covering the Introduction,  Marketed Products, Product Pipeline, Late-Stage Drugs in Developmental Pipeline, Market Forecast, Drivers and Barriers, Deals, Appendix.

Know more about this report: http://mrr.cm/ZNK

Glioblastoma Multiforme Therapeutics Market is expected to grow rapidly from $305m to $583m During 2012 to 2019, Reveals New Report

“Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany”. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck’s Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche’s Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment.

During the 2012-2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m. The market entry of Northwest Biotherapeutics’ DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline.

Scope

A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis:

• In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy
• A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target
• Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate
• Multi-scenario forecast data for the GBM market to 2019, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain
• Discussion of the drivers of and barriers to market growth
• Discussion of the licensing and co-development deals landscape in GBM

Reasons to buy

• Understand the different levels of GBM therapies for newly diagnosed and recurrent GBM
• Understand the vast scope of the pipeline and determine which molecule types and mechanisms of action are prominent
• Observe the trends in clinical trial duration and size by clinical Phase and molecule type, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for GBM therapeutics
• Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the GBM therapeutics market

Spanning over 112 pages, “Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany” report covering the Marketed drugs, Glioblastoma Pipeline, Market forecasts, Deals and Strategic Consolidations, Appendix

Know more about this report: http://mrr.cm/ZML

The Breast Cancer Therapeutics Markets ( US, UK, France, Germany, Spain, Italy, Japan and Canada) is expected to reach $13.1 billion by 2020, Reveals New Report

"Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs", which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The breast cancer therapeutics market in the eight major markets - The US, The UK, France, Germany, Spain, Italy, Japan and Canada - was worth $9.2 billion in 2013, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.1% to $13.1 billion by 2020. The US had the largest market in 2013, valued at $5.5 billion, equivalent to a global share of 59%, followed by Japan with $871.5m or 9.4% and Italy with $668.5m or 7.2%. Canada had the lowest market share and value of the leading eight at 2.9% and $268.4m, but is expected to witness rapid growth over the forecast period with a CAGR of 6.7%. This will only be surpassed by Japan, which is expected to witness growth at a CAGR of 6.9%.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer in the major developed markets. The report includes:

• Disease overview, as well as treatment algorithms and treatment usage patterns
• Market size and forecast for the breast cancer market from 2012 to 2019
• Major marketed products for breast cancer along with a heat map of product performance
• In-depth pipeline analysis for global pipeline in breast cancer along with clinical trial failure rate analysis
• Key drivers and restraints that have had and are expected to have a significant impact upon the market
• Key licensing and co-development agreements that could have impact on growth trends

Reasons to buy

The report will enhance your decision-making capability by allowing you to:

• Align your product portfolio to the markets with high growth potential
• Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
• Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer therapeutics market
• Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Spanning over 106 pages, “Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs” report covering the Breast Cancer Therapeutics in Major Developed Markets to 2020 - Introduction, Breast Cancer Therapeutics in Major Developed Markets to 2020 - Marketed Products, Breast Cancer Therapeutics in Major Developed Markets to 2020 - Pipeline Analysis, Breast Cancer Therapeutics in Major Developed Markets to 2020 - Market Forecast to 2020, Breast Cancer Therapeutics in Major Developed Markets to 2020 - Deals and Strategic Consolidations, Breast Cancer Therapeutics in Major Developed Markets to 2020 - Appendix.

Know more about this report: http://mrr.cm/ZME

Glioblastoma Multiforme Therapeutics Market in Asia-Pacific Region to Post High Growth to Reach $105.8m by 2020, Reveals New Report

The Glioblastoma Multiforme (GBM) therapeutics market in the four Asia-Pacific (APAC) markets of Australia, China, India and Japan was worth $49.4m in 2013, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 11.5% to $105.8m by 2020. Japan was the largest of these markets in 2013, valued at $23.8m, equivalent to a share of 48%, closely followed by China at $19.7m or 40%. This significant expected growth is due to the probable approval and market entries of Rindopepimut (CDX-110), Cotara (TNT-1) and Avastin (bevacizumab) in some of the APAC regions during the forecast period.

India and Australia have more promising candidates for possible approval in the forecast period than China and Japan. The growth forecast for Japan, however, is still high, even though it has just one candidate in late-stage development that could be approved during the forecast period, due to recent approval of Avastin. Japan is expected to post a high CAGR of 13.8%, second only to India among the APAC countries. The GBM market in India is currently the smallest, estimated at $4.6m in 2013, but is expected to post the highest growth, at a CAGR of 14.4% until 2020. There are four promising GBM drugs in the pipeline in India that could have a significant impact on market growth – Rindopepimut and BIOMAb (nimotuzumab) for newly diagnosed GBM; Avastin and Cotara for treatment in the recurrent setting.

The pipeline presents two promising novel therapies – Rindopepimut and Cotara – that could have a significant bearing on the GBM market in the APAC region. Phase II studies of Rindopepimut demonstrated a relatively high median Overall Survival (OS), and a significant survival benefit when compared to historic controls treated with the standard of care. However, the vaccine is limited to the 30% of GBM patients who are Epidermal Growth Factor Receptor (EGFR) variant (v) III-positive. Phase II studies of Cotara showed similar OS to Avastin, with slightly better Progression Free Survival (PFS) improvement in recurrent GBM. As a single-infusion therapy, Cotara is likely to become a good alternative second-line treatment.

Pipeline Boasts High Diversity of Molecular Targets Despite Setbacks

Several targeted therapies have failed in late-stage development or have shown too little efficacy to be viable therapeutic alternatives. Growth Factor Receptors (GFR) are one of the most prevalent molecular targets in the GBM pipeline. Although EGFR gene amplification is the most common mutation seen in GBM patients, several drugs with EGFR as molecular targets have failed to demonstrate significant efficacy. Drugs that target EGFR but that failed to demonstrate significant benefit in improving median OS or PFS include Tarceva (erlotinib), Erbitux (cetuximab), and Iressa (gefitinib). Vascular Endothelial Growth Factor Receptor (VEGFR)-targeting drugs such as Recentin (cediranib) have also experienced some setbacks. Currently, Avastin (bevacizumab) is the only anti-VEGFR agent marketed for GBM. Despite these setbacks, the GBM pipeline consists of a sizeable share of drugs targeting GFRs – 35% – with some of them reaching late-stage development. EGFR inhibitors in the late-stage pipeline include ABT-414, gefitinib, AMG-595, and nimotuzumab. Similarly, 17% of the disclosed pipeline consists of kinases. While the majority of Phosphoinositide 3-Kinase (PI3K) inhibitors are unable to cross the Blood–Brain Barrier (BBB), 22% of the kinases in the GBM pipeline are PI3K inhibitors. PX-866, a PI3K inhibitor developed by Oncothyreon, was discontinued in Phase II development due to low efficacy. BKM-120 (buparlisib hydrochloride) is another PI3K inhibitor currently in Phase II trials for recurrent GBM. The current pipeline consists of a highly diverse set of molecular targets, which may potentially serve as effective treatments in the future.

Promising Future for Glioblastoma Multiforme Therapeutic Landscape

GBM is the most malignant of gliomas, which are an aggressive type of tumor with very poor prognosis, in spite of the improvements seen with the current standard of care temozolomide. There are very limited therapeutic alternatives currently available for newly diagnosed or recurrent GBM. Existing options include three chemotherapeutic agents – temozolomide, Gliadel Wafer (carmustine in polifeprosan) and BiCNU (carmustine); and Avastin, a monoclonal Antibody (mAb), which is the only approved targeted therapy. Extensive heterogeneity and the presence of the BBB are the two key challenges in the development of efficacious therapeutic options. Many of the existing chemotherapy drugs are hydrophilic and their molecular size is too large to penetrate the BBB and hence not suitable in the treatment of GBM.

There are some strong candidates in the current pipeline that promise to be effective agents in overcoming the BBB. Examples include BIOMAb (nimotuzumab) by Biocon, a mAb and an EGFR antagonist that binds preferentially to the cells overexpressing EGFR and holds promise in its capacity to cross the BBB; and Cotara, a targeted mAb developed by Peregrine Pharmaceuticals that uses Convection-Enhanced Delivery (CED) to overcome the BBB and is in Phase II trials for newly diagnosed GBM; and BKM-120 (buparlisib hydrochloride) developed by Novartis, a PI3K inhibitor in Phase II trials for recurrent GBM with proven ability to penetrate the BBB. Although a cure is not expected in the near future, the late-stage pipeline presents some strong candidates that have the potential to expand the therapeutic alternatives available for GBM.

Spanning over 105 pages, “Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM” report covering the Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Introduction, Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Marketed Products, Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Pipeline, Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Market Forecast to 2020, Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Deals and Strategic Consolidations, Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Appendix.

Know more about this report: http://mrr.cm/ZXC

Browse more Diagnostics reports at: http://www.marketresearchreports.com/diagnostics

The Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Expected to Reach $9.9billion by 2020, Reveals New Report

The Attention-Deficit Hyperactivity Disorder (ADHD) therapeutics market value will rise from $6.9 billion in 2013 to $9.9 billion by 2020, with broadening diagnostic criteria a key driver of growth, according to ADHD therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations report.

This report states that this increase, which represents a Compound Annual Growth Rate (CAGR) of 5.3% and relates to eight major markets (the US, the UK, France, Germany, Spain, Italy, Japan and Canada), will occur fastest in Japan, due to its high ADHD prevalence.

Despite the stigma attached to mental health conditions, this country will witness a more impressive ADHD treatment market CAGR of 15.7%.

Senior Analyst says: “ADHD prevalence will rise steadily across the major markets, from approximately 15 million cases in 2013 to just over 18 million by 2020. However, diagnosis rates are particularly low outside of the US, as the disorder is still treated with considerable skepticism.

“Debate remains about the fear of under- or over-diagnosis, the causes and legitimacy of ADHD as a condition, and the skew towards greater prevalence in the US. Research has suggested that ADHD is just as prevalent in other countries as in the US, but it is significantly more recognized in this market.”

Prior notes that this trend is expected to change over the coming decade, due largely to an increased recognition of adult ADHD.

The fifth edition of The Diagnostic and Statistical Manual of Mental Disorders, which was published in 2013, broadened the diagnostic criteria for ADHD, recognizing that impairment from symptoms of the disorder may develop in later life.

Analyst says: “These developments herald the final acceptance of adult ADHD in a clinical setting and mean that many people who met the ‘partial remission’ criteria will now meet the full criteria, leading to an increase in diagnosis.

“However, the continuing reluctance of many patients to seek treatment for mental health conditions will be a barrier to ADHD diagnosis rates, and consequently to any further market growth.”

ADHD therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations report provides analysis of the currently marketed Attention-Deficit Hyperactivity Disorder (ADHD) drugs, including recent sales figures and safety and efficacy data, across eight major markets (8MM: the US, Canada, UK, France, Germany, Italy, Spain and Japan). It also provides comprehensive reviews of the ADHD drugs pipeline and in-depth, multi-scenario forecasts for ADHD therapeutics in the 8MM up to 2018.

Spanning over 91 pages, “ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations” report covering the Introduction, Marketed Products, ADHD Pipeline, Market Forecast to 2020, Deals and Strategic Consolidations, Appendix.

Know more about this report: http://mrr.cm/ZX9

Exenatide - Comprehensive patent search, New Report Launched

Exenatide - Comprehensive patent search: Imagine having your own team of pharmaceutical patent experts at the click of a button.

Used by the world’s leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won’t need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on your business, rather than getting bogged down in patent data.

Eliminate bottlenecks and free up months of expert manpower

• Over 350 fully researched and updated patent searches by highly trained, qualified staff using proprietary searching techniques, available for instant online access
• Intuitive, easy to understand design provides vital documents at your fingertips
• Collaborate and share company knowledge with online access to notes and flags

Quickly grasp complexity

• Identifies patents covering molecule, formulation, process, use, combinations and more
• Grouped by patent family and assigned to development categories based on interpretation of key aspects of the patent claims
• Manual filtration of patents so you only see what is relevant to you
• Covers the world’s major territories with equivalents in over 80 countries

Never miss a change in the patent landscape

• Monthly updates to patent families, statuses, and litigation clearly identified
• Comprehensive litigation alerts linked to patent numbers
• Add your own notes, save searches and results

This report covers:

• International Nonproprietary Name:  Cefovecin (Vet)
• indications: Treatment of skin, soft tissue, urinary tract, and severe periodontal infections optionally in combination with mechanical or - surgical periodontal therapy (cat, dog)
• innovator:Pfizer (Convenia), Zoetis (Convenia)

Country coverage:

The In-depth search contains patents from territories that are individually verified and monitored for changes, including British, German, Spanish, French, US, Canadian, Australian, European, and PCT patents. 

Access: This report is provided through an online portal for a period of 12 months, for a maximum of 5 users.  During this period, access to updates, excel exports, patent documents and national registers is provided at no additional charge.

In-depth Search features:

• Comprehensive patent searching, covering the world's key territories
• Identifies patents covering molecule, formulation, process, use, combinations and more (see 'Patent Categories Identified below)
• Patent identification, categorisation and interpretation
• Grouped by patent family and assigned to development categories based on Interpretation of key aspects of the patent claims
• Comprehensive litigation alerts linked to patent numbers
• Monthly updates to patent families, statuses, and litigation clearly identified
• Enables fast analysis and verification by hyper-linking to crucial patent documents and national registers
• Add your own notes, save searches and results

Know More About This Report: http://mrr.cm/ZX2

Eculizumab - Comprehensive patent search, New Report Launched

Eculizumab - Comprehensive patent search: Imagine having your own team of pharmaceutical patent experts at the click of a button.

Used by the world’s leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won’t need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on your business, rather than getting bogged down in patent data.

Eliminate bottlenecks and free up months of expert manpower

• Over 350 fully researched and updated patent searches by highly trained, qualified staff using proprietary searching techniques, available - for instant online access
• Intuitive, easy to understand design provides vital documents at your fingertips
• Collaborate and share company knowledge with online access to notes and flags

Quickly grasp complexity

• Identifies patents covering molecule, formulation, process, use, combinations and more
• Grouped by patent family and assigned to development categories based on interpretation of key aspects of the patent claims
• Manual filtration of patents so you only see what is relevant to you
• Covers the world’s major territories with equivalents in over 80 countries

Never miss a change in the patent landscape

• Monthly updates to patent families, statuses, and litigation clearly identified
• Comprehensive litigation alerts linked to patent numbers
• Add your own notes, save searches and results

This report covers:

• International Nonproprietary Name:  Cefovecin (Vet)
• indications: Treatment of skin, soft tissue, urinary tract, and severe periodontal infections optionally in combination with mechanical or surgical periodontal therapy (cat, dog)
• innovator:Pfizer (Convenia), Zoetis (Convenia)

Country coverage:

The In-depth search contains patents from territories that are individually verified and monitored for changes, including British, German, Spanish, French, US, Canadian, Australian, European, and PCT patents. 

Access: This report is provided through an online portal for a period of 12 months, for a maximum of 5 users.  During this period, access to updates, excel exports, patent documents and national registers is provided at no additional charge.

In-depth Search features:

• Comprehensive patent searching, covering the world's key territories
• Identifies patents covering molecule, formulation, process, use, combinations and more (see 'Patent Categories Identified below)
• Patent identification, categorisation and interpretation
• Grouped by patent family and assigned to development categories based on Interpretation of key aspects of the patent claims
• Comprehensive litigation alerts linked to patent numbers
• Monthly updates to patent families, statuses, and litigation clearly identified
• Enables fast analysis and verification by hyper-linking to crucial patent documents and national registers
• Add your own notes, save searches and results

Know More About This Report: http://mrr.cm/ZXz

Aflibercept - Comprehensive patent search, New Report Launched

Aflibercept - Comprehensive patent search: Imagine having your own team of pharmaceutical patent experts at the click of a button.

Used by the world’s leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won’t need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on your business, rather than getting bogged down in patent data.

Eliminate bottlenecks and free up months of expert manpower

• Over 350 fully researched and updated patent searches by highly trained, qualified staff using proprietary searching techniques, available for instant online access
• Intuitive, easy to understand design provides vital documents at your fingertips
• Collaborate and share company knowledge with online access to notes and flags

Quickly grasp complexity

• Identifies patents covering molecule, formulation, process, use, combinations and more
• Grouped by patent family and assigned to development categories based on interpretation of key aspects of the patent claims
• Manual filtration of patents so you only see what is relevant to you
• Covers the world’s major territories with equivalents in over 80 countries

Never miss a change in the patent landscape

• Monthly updates to patent families, statuses, and litigation clearly identified
• Comprehensive litigation alerts linked to patent numbers
• Add your own notes, save searches and results

This report covers:

• International Nonproprietary Name:  Cefovecin (Vet)
• indications: Treatment of skin, soft tissue, urinary tract, and severe periodontal infections optionally in combination with mechanical or surgical periodontal therapy (cat, dog)
• innovator:Pfizer (Convenia), Zoetis (Convenia)

Country coverage:

The In-depth search contains patents from territories that are individually verified and monitored for changes, including British, German, Spanish, French, US, Canadian, Australian, European, and PCT patents. 

Access: This report is provided through an online portal for a period of 12 months, for a maximum of 5 users.  During this period, access to updates, excel exports, patent documents and national registers is provided at no additional charge.

In-depth Search features:

• Comprehensive patent searching, covering the world's key territories
• Identifies patents covering molecule, formulation, process, use, combinations and more (see 'Patent Categories Identified below)
• Patent identification, categorisation and interpretation
• Grouped by patent family and assigned to development categories based on Interpretation of key aspects of the patent claims
• Comprehensive litigation alerts linked to patent numbers
• Monthly updates to patent families, statuses, and litigation clearly identified
• Enables fast analysis and verification by hyper-linking to crucial patent documents and national registers
• Add your own notes, save searches and results

Know More About This Report: http://mrr.cm/ZXh